Loss of liver kinase B1 (LKB1, also known as serine/threonine kinase 11 or STK11) in non-small cell lung cancer (NSCLC) has been shown to enrich these tumors with KEAP1 mutations, making these cancers vulnerable to inhibition of NRF2-mediated antioxidant response [164]. The gene discussed is NFE2L2; the disease is cancer.